Name | Title | Contact Details |
---|---|---|
Jeff Huber |
Chief Executive Officer | Profile |
NanoLogix is a biotechnology company specializing in live cell, rapid diagnostics. Our kits are simple and reliable rapid test solutions that detect active threat bacteria and other microorganisms 4x - 12x faster than traditional Petri culture technology, and more cost effectively than PCR Protocol. NanoLogix FlatPack packaging allows for an extended shelf-life that is frequently more than double today's standard. In ongoing shelf-life tests, NanoLogix plates containing TSA media in FlatPacks have maintained nutrient and moisture levels for over two years in cold storage and over one year at room temperature (RT). Other agars have their usable shelf lives extended by varying amounts. NanoLogix plates can be used for isolating microorganisms, total plate count, and for maintaining stock cultures.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.
We have developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques in molecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan`s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer